Lipocine (NASDAQ:LPCN) Given Neutral Rating at HC Wainwright

Lipocine (NASDAQ:LPCN)‘s stock had its “neutral” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports.

LPCN has been the subject of a number of other reports. Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lipocine in a research note on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Lipocine currently has a consensus rating of “Hold” and a consensus target price of $15.00.

Lipocine Stock Performance

LPCN opened at $2.05 on Monday. The stock has a market cap of $14.97 million, a price-to-earnings ratio of -1.22 and a beta of 1.09. The firm’s fifty day moving average is $8.27 and its 200 day moving average is $5.78. Lipocine has a fifty-two week low of $1.81 and a fifty-two week high of $12.37.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.26. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.The business had revenue of $1.15 million during the quarter, compared to analyst estimates of $0.12 million.

Insider Buying and Selling at Lipocine

In related news, CEO Mahesh V. Patel purchased 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The shares were bought at an average price of $2.02 per share, for a total transaction of $50,500.00. Following the acquisition, the chief executive officer owned 135,679 shares of the company’s stock, valued at approximately $274,071.58. This represents a 22.59% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 6.35% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of LPCN. Citadel Advisors LLC bought a new position in Lipocine during the third quarter valued at $41,000. Jane Street Group LLC purchased a new position in shares of Lipocine during the 4th quarter worth about $85,000. Renaissance Technologies LLC boosted its stake in shares of Lipocine by 3.6% during the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after purchasing an additional 1,300 shares during the period. Boothbay Fund Management LLC bought a new position in Lipocine during the 4th quarter valued at about $441,000. Finally, Geode Capital Management LLC raised its position in Lipocine by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock worth $502,000 after purchasing an additional 1,374 shares during the period. 9.11% of the stock is owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.